Finanzen von Acrivon Therapeutics, Inc. (ACRV)ACRVAcrivon Therapeutics, Inc.

Evaluating the bottom line, Acrivon Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.63%, provide a clear picture of how effectively ACRV converts its operational activities into shareholder value.

In the context of the broader market, ACRV competes directly with industry leaders such as DWTX and ACET. With a market capitalization of $83.56M, it holds a significant position in the sector. When comparing efficiency, ACRV's gross margin of N/A stands against DWTX's N/A and ACET's N/A. Such benchmarking helps identify whether Acrivon Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Acrivon has been experiencing significant losses, with a net income of -$19,064,000 for Q2 2026 and a negative EPS of -0.43 for the same quarter. However, it has a strong current ratio of 7.99, indicating good short-term financial health.